Arrowpoint Investment Partners’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-4,934
Closed -$1.74M 131
2026
Q1
$1.74M Sell
4,934
-1,025
-17% -$365K 1.54% 16
2025
Q4
$1.95M Buy
5,959
+5,859
+5,859% +$1.86M 0.29% 31
2025
Q3
$28.2K Buy
+100
New +$29K 0.03% 77
2025
Q1
Sell
-5,070
Closed -$1.32M 921
2024
Q4
$1.32M Buy
+5,070
New +$1.5M 0.27% 82

Other funds holding AMGN

Arrowpoint Investment Partners's AMGN Position: Q2 2026 in Review

Arrowpoint Investment Partners sold out of Amgen (AMGN) in Q2 2026, closing a stake of 4,934 shares — an estimated $1.74M sold.

Arrowpoint Investment Partners first reported a position in AMGN in Q4 2024 and held it in 4 quarters. The position peaked at $1.95M in Q4 2025. 3,156 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Arrowpoint Investment Partners reported no remaining Amgen position as of Q2 2026 after selling out during the quarter.
  • Arrowpoint Investment Partners sold 4,934 Amgen shares in Q2 2026, an estimated $1.74M.
  • Arrowpoint Investment Partners first reported a position in Amgen in Q4 2024 and held it in 4 quarters.
  • Arrowpoint Investment Partners's Amgen position peaked at $1.95M in Q4 2025.
  • 3,156 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.